What's New After NICE Acne Guidelines.
Acne vulgaris
Antibiotics
Assessment
Management
Truncal acne
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
21 Sep 2024
21 Sep 2024
Historique:
received:
04
06
2024
accepted:
06
09
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
Acne remains one of the most common inflammatory dermatoses seen worldwide. There are significant challenges when managing acne relating to a variety of factors, including (1) lack of consensus on the use of the numerous available grading systems and outcome measures, (2) appreciation of the numerous areas that relate to severity, (3) the chronic nature of acne which requires a longitudinal approach to management (including both facial and truncal disease), and (4) the need to target acne early to avoid physical and psychosocial scarring. Consideration of these aspects when managing acne should result in improved outcomes. Acne guidelines review the available evidence based on robust clinical trials and are usually supplemented with some expert opinion when evidence is not available. In this paper, the UK Acne Working Group reflects on the latest National Institute for Health and Care Excellence (NICE) acne guidelines with a goal of providing additional practical insights. The group have identified areas where new evidence has now become available since the formulation of the NICE acne guidelines. This publication considers newly approved acne medications in the UK, guidance on assessing acne severity, approaches to managing truncal acne, acne sequelae, and adult female acne with hormonal therapies. The National Institute for Health and Care Excellence (NICE) produced acne guidelines in June 2021 for clinicians and patients. New evidence and information on practical aspects of acne management have emerged since this time. A panel of clinicians with expertise in acne discuss herein some areas of interest that may support acne management, some of which could be considered in a second iteration of NICE acne guidelines. These areas include how to assess acne, the medical approach to truncal acne, how clinicians may manage the long-lasting acne sequelae of scarring and darkly pigmented spots, and the use of medical hormonal therapies for women (such as birth control pills) to manage acne that may have a causative contribution of hormone imbalances.
Autres résumés
Type: plain-language-summary
(eng)
The National Institute for Health and Care Excellence (NICE) produced acne guidelines in June 2021 for clinicians and patients. New evidence and information on practical aspects of acne management have emerged since this time. A panel of clinicians with expertise in acne discuss herein some areas of interest that may support acne management, some of which could be considered in a second iteration of NICE acne guidelines. These areas include how to assess acne, the medical approach to truncal acne, how clinicians may manage the long-lasting acne sequelae of scarring and darkly pigmented spots, and the use of medical hormonal therapies for women (such as birth control pills) to manage acne that may have a causative contribution of hormone imbalances.
Identifiants
pubmed: 39305432
doi: 10.1007/s13555-024-01275-0
pii: 10.1007/s13555-024-01275-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
National Institute for Health and Care Excellence. Acne vulgaris: management. 2021.
Gollnick HP, Finlay AY, Shear N, Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9:279–84.
doi: 10.2165/00128071-200809050-00001
pubmed: 18717602
Centers for disease control and prevention. National center for health statistics. Classifications of diseases and functioning and disability. http://www.cdc.gov/nchs/about/otheract/icd9/icfhome.htm . Accessed 30 July 2024.
Akinboro AO, Ezejiofor OI, Olanrewaju FO, et al. The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates. Clin Cosmet Investig Dermatol. 2018;11:245–52.
doi: 10.2147/CCID.S158129
pubmed: 29785134
pmcid: 5955012
Eichenfield DZ, Sprague J, Eichenfield LF. Management of acne vulgaris: a review. JAMA. 2021;326:2055–67.
doi: 10.1001/jama.2021.17633
pubmed: 34812859
Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140:672–6.
doi: 10.1046/j.1365-2133.1999.02768.x
pubmed: 10233319
Chuah SY, Goh CL. The impact of post-acne scars on the quality of life among young adults in Singapore. J Cutan Aesthet Surg. 2015;8:153–8.
doi: 10.4103/0974-2077.167272
pubmed: 26644739
pmcid: 4645145
Hayashi N, Miyachi Y, Kawashima M. Prevalence of scars and “mini-scars”, and their impact on quality of life in Japanese patients with acne. J Dermatol. 2015;42:690–6.
doi: 10.1111/1346-8138.12885
pubmed: 25916427
Tan JK, Li Y, Fung K, et al. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg. 2008;12:235–42.
doi: 10.2310/7750.2008.07053
pubmed: 18845093
Schuster B, Gallinger J, Philipp-Dormston WG, Vasel M, Layton AM. Less confident, successful and happy: patients with post-acne hyperpigmentation are stigmatized. Br J Dermatol. 2023;188:682–4.
doi: 10.1093/bjd/ljad026
pubmed: 36722369
Pathmarajah P, Peterknecht E, Cheung K, Elyoussfi S, Muralidharan V, Bewley A. Acne vulgaris in skin of color: a systematic review of the effectiveness and tolerability of current treatments. J Clin Aesthet Dermatol. 2022;15:43–68.
pubmed: 36381183
pmcid: 9651155
Tan J, Beissert S, Cook-Bolden F, Chavda R, Harper J, Hebert A, et al. Impact of facial atrophic acne scars on quality of life: a multi-country population-based survey. Am J Clin Dermatol. 2022;23:115–23.
doi: 10.1007/s40257-021-00628-1
pubmed: 34705166
Layton A, Alexis A, Baldwin H, et al. Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the personalising acne: consensus of experts panel. JAAD Int. 2021;5:41–8.
doi: 10.1016/j.jdin.2021.06.006
pubmed: 34816133
pmcid: 8593750
Anaba EL, Oaku RI. Cross-sectional study of beliefs, perceptions, knowledge of treatment modalities and willingness to pay for acne scar treatment in acne patients. West Afr J Med. 2020;37:625–30.
pubmed: 33185257
Dreno B, Tan J, Kang S, et al. How people with facial acne scars are perceived in society: an online survey. Dermatol Ther (Heidelb). 2016;6:207–18.
doi: 10.1007/s13555-016-0113-x
pubmed: 27090421
Gieler U, Gieler T, Kupfer JP. Acne and quality of life - impact and management. J Eur Acad Dermatol Venereol. 2015;29(Suppl 4):12–4.
doi: 10.1111/jdv.13191
pubmed: 26059729
Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on quality of life: a multi-country population-based survey. JAAD Int. 2021;3:102–10.
doi: 10.1016/j.jdin.2021.03.002
pubmed: 34409378
pmcid: 8362284
Brodell RT, Schlosser BJ, Rafal E, et al. A fixed-dose combination of adapalene 0.1%-BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. J Dermatolog Treat. 2012;23:26–34.
doi: 10.3109/09546634.2011.643221
pubmed: 22103674
Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology. 2008;217:309–14.
doi: 10.1159/000151441
pubmed: 18714158
Goh CL, Wu Y, Welsh B, et al. Expert consensus on holistic skin care routine: focus on acne, rosacea, atopic dermatitis, and sensitive skin syndrome. J Cosmet Dermatol. 2023;22:45–54.
doi: 10.1111/jocd.15519
pubmed: 36409588
Stein Gold L, Tan J, Kircik L. Evolution of acne assessments andimpact on acne medications: an evolving, imperfect paradigm. J Drugs Dermatol. 2016;15:79–86.
pubmed: 26741385
Tan J, Alexis A, Baldwin H, et al. The personalised acne care pathway-recommendations to guide longitudinal management from the personalising acne: consensus of experts. JAAD Int. 2021;5:101–11.
doi: 10.1016/j.jdin.2021.09.006
pubmed: 34816135
pmcid: 8593752
Tan J, Del Rosso JQ, Weiss JS, et al. Prevalence and demographics of truncal involvement among acne patients: survey data and a review of the literature. J Clin Aesthet Dermatol. 2022;15:62–7.
pubmed: 36312821
pmcid: 9586532
Tan J, Alexis A, Baldwin H, et al. Gaps and recommendations for clinical management of truncal acne from the personalising acne: consensus of experts panel. JAAD Int. 2021;5:33–40.
doi: 10.1016/j.jdin.2021.06.007
pubmed: 34816132
pmcid: 8593751
Tan JK, Tang J, Fung K, et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg. 2007;11:211–6.
doi: 10.2310/7750.2007.00037
pubmed: 18042334
Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment. Cutis. 2006;77:285–9.
pubmed: 16776282
Liu C-W, Tan J. Understanding truncal acne: a practical guide to diagnosis and management. Skin Therapy Letter. http://www.skintherapyletter.com/conditions/acne/truncal-diagnosis-management/ . Accessed 16 July 2018.
Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80:1691–9.
doi: 10.1016/j.jaad.2019.02.044
pubmed: 30802558
Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179:442–56.
pubmed: 29974453
Woo YR, Kim HS. Truncal acne: an overview. J Clin Med. 2022;11:3660.
doi: 10.3390/jcm11133660
pubmed: 35806952
pmcid: 9267677
Thiboutot D, Dreno B, Abanmi A, et al. Practical management of acne for clinicians. An international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2017.09.078 .
doi: 10.1016/j.jaad.2017.09.078
pubmed: 29127053
Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the Unites States. J Drugs Dermatol. 2017;16:97–102.
pubmed: 28300850
Tan J, Thiboutot D, Gollnick H, et al. Development of an atrophic acne scar risk assessment tool. J Eur Acad Dermatol Venereol. 2017. https://doi.org/10.1111/jdv.14325 .
doi: 10.1111/jdv.14325
pubmed: 29114947
Schleicher S, Moore A, Rafal E, et al. Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study. Dermatol Ther (Heidelb). 2023. https://doi.org/10.1007/s13555-023-01042-7 .
doi: 10.1007/s13555-023-01042-7
pubmed: 37838987
Dreno B, Bissonnette R, Gagne-Henley A, et al. Long-term effectiveness and safety of up to 48 weeks’ treatment with topical adapalene 0.3%/benzoyl peroxide 2.5% gel in the prevention and reduction of atrophic acne scars in moderate and severe facial acne. Am J Clin Dermatol. 2019;20:725–32.
doi: 10.1007/s40257-019-00454-6
pubmed: 31209851
Tan JK, Tang J, Fung K, et al. Development and validation of a scale for acne scar severity (SCAR-S) of the face and trunk. J Cutan Med Surg. 2010;14:156–60.
doi: 10.2310/7750.2010.09037
pubmed: 20642983
Alexis A, Del Rosso J, Forman S, et al. Efficacy and safety of trifarotene cream 50µg/g for the treatment of acne-induced post-inflammatory hyperpigmentation in subjects with Fitzpatrick skin types I-VI: results from a phase IV trial (LEAP). Berlin Germany: European Academy of Dermatology and Venereology; 2023.
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(945–73):e33.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18:169–91.
doi: 10.1007/s40257-016-0245-x
pubmed: 28155090
pmcid: 5360829
Santer M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. 2023;381:e074349.
doi: 10.1136/bmj-2022-074349
pubmed: 37192767
pmcid: 10543374
Barbieri JS, Choi JK, Mitra N, Margolis DJ. Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010–2016. J Drugs Dermatol. 2018;17:632–8.
pubmed: 29879250
Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017;3:111–5.
doi: 10.1016/j.ijwd.2016.12.002
pubmed: 28560306
pmcid: 5440451
Thiede RM, Rastogi S, Nardone B, et al. Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (research on adverse drug events and reports) program. Int J Women’s Dermatol. 2019;5:155–7.
doi: 10.1016/j.ijwd.2019.04.024
Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151:941–4.
doi: 10.1001/jamadermatol.2015.34
pubmed: 25796182